hyogo.publishing.3rd-in.co.jp
オルガノイド研究の最前線を知る!住友ベークライトのウェブセミナー開催
住友ベークライトが開催するオルガノイドに関するウェブセミナー。創薬研究の最前線を体感できる貴重な機会をお見逃しなく!
#創薬 is an active hashtag on Bluesky. In the last 30 days, 6 people shared 22 posts with it — around 1 a day. Activity is down 25% versus the previous week, peaking on Aug 5 with 4 posts.
hyogo.publishing.3rd-in.co.jp
オルガノイド研究の最前線を知る!住友ベークライトのウェブセミナー開催
住友ベークライトが開催するオルガノイドに関するウェブセミナー。創薬研究の最前線を体感できる貴重な機会をお見逃しなく!
tokyo.publishing.3rd-in.co.jp
後藤祐吾氏が株式会社4DINのCSOに就任し、医療データ活用を加速
後藤祐吾が株式会社4DINの最高戦略責任者に就任。医療データ活用と創薬現場の課題解決を目指し、事業展開を本格化。
arxiv.org
EpiBench: Can LLMs Understand Epitopes for Antibody Drug Discovery?
Epitopes determine where antibodies bind antigens and shape downstream therapeutic properties such as functional blockade and escape resistance, making epitope understanding central to antibody drug discovery. Although large language models (LLMs) have shown strong biomedical reasoning ability, it remains unclear whether they can infer epitope information directly from antigen and antibody sequences. Existing epitope resources typically focus on isolated prediction tasks or rely on specialized structural settings, while general protein benchmarks do not evaluate epitope-centered decisions across the antibody development workflow. To address this gap, we introduce EpiBench, a closed-book, sequence-based, and automatically scorable benchmark for evaluating epitope reasoning in LLMs. EpiBench contains 1,609 curated samples grounded in structural antibody--antigen contacts, curated functional B-cell assays, and deep mutational scanning escape measurements. It covers five connected tasks: t
arxiv.org
EpiBench: Can LLMs Understand Epitopes for Antibody Drug Discovery?
Epitopes determine where antibodies bind antigens and shape downstream therapeutic properties such as functional blockade and escape resistance, making epitope understanding central to antibody drug discovery. Although large language models (LLMs) have shown strong biomedical reasoning ability, it remains unclear whether they can infer epitope information directly from antigen and antibody sequences. Existing epitope resources typically focus on isolated prediction tasks or rely on specialized structural settings, while general protein benchmarks do not evaluate epitope-centered decisions across the antibody development workflow. To address this gap, we introduce EpiBench, a closed-book, sequence-based, and automatically scorable benchmark for evaluating epitope reasoning in LLMs. EpiBench contains 1,609 curated samples grounded in structural antibody--antigen contacts, curated functional B-cell assays, and deep mutational scanning escape measurements. It covers five connected tasks: t
hyogo.publishing.3rd-in.co.jp
オルガノイド研究の最前線を知る!住友ベークライトのウェブセミナー開催
住友ベークライトが開催するオルガノイドに関するウェブセミナー。創薬研究の最前線を体感できる貴重な機会をお見逃しなく!
tokyo.publishing.3rd-in.co.jp
後藤祐吾氏が株式会社4DINのCSOに就任し、医療データ活用を加速
後藤祐吾が株式会社4DINの最高戦略責任者に就任。医療データ活用と創薬現場の課題解決を目指し、事業展開を本格化。
news.3rd-in.co.jp
理研と国立がん研究センターが切り開く日本の創薬革命
理化学研究所と国立がん研究センターが、日本の創薬力を強化するためのシンポジウムを開催。未来の医薬品開発の可能性に迫ります。
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.